We currently have three portfolio companies each advancing specific assets in various stages of development that address significant unmet needs:

Nuralis Pharmaceuticals is an Oncology portfolio company developing an innovative, first-in-class therapy for the detection of recurrence and the treatment of thyroid cancer.

Giovel Pharmaceuticals is a Gastroenterology portfolio company developing a novel, first-in-class therapy for gastroparesis and functional dyspepsia.

Giathera Pharmaceuticals is a Gastroenterology portfolio company developing potentially the first product to be approved to treat Parkinson’s disease patients with certain GI motility-related disorders.

Discover Innovative and Efficient Drug Development

Contact Us